Previous 10 | Next 10 |
- Posoleucel (Viralym-M, ALVR105) proof-of-concept studies in multi-virus prevention in stem cell transplant patients and BK viremia in kidney transplant patients continue to progress with initial data expected 4Q21 - Posoleucel Phase 3 pivotal trial in virus-associated hemorr...
AlloVir (ALVR): Q1 GAAP EPS of -$0.50 misses by $0.08.Cash, cash equivalents, and marketable securities of $337M.Press Release For further details see: AlloVir EPS misses by $0.08
- Viralym-M pivotal trial in virus-associated hemorrhagic cystitis continues to progress enrollment - Viralym-M proof-of-concept studies in multi-virus prevention in stem cell transplant and BK viremia in kidney transplant continue to progress with initial data expected 4Q21 ...
Uses same technology as MRKR, which I covered earlier. Has a later stage and much more successful program in infectious diseases in HSCT patients. Current depressed prices and upcoming catalysts make it a buy. For further details see: AlloVir: Targeting Infectious Diseas...
Calling the company ‘an oncology diamond,’ Evercore ISI has initiated coverage on Viracta Therapeutics ([[VIRX]] +11.5%) with an outperform rating. Its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas underlies the firm’s thesis.The price target ...
Updated interim data provided by AstraZeneca (AZN) yesterday from its late-stage COVID-19 vaccine trial in the U.S., should address the data integrity issue, UBS wrote in a note. AstraZeneca ADRs are trading marginally up in before hours.The Analysts led by Michael Leuchten with a buy ra...
AlloVir (ALVR) appoints Diana M. Brainard, M.D., as the company’s CEO, effective May 17, 2021. She has served on AlloVir’s BOD since April 2019, initially as a Board Observer, and as an Independent Director since July 2020. Dr. Brainard currently se...
- David Hallal to continue as Executive Chairman of the AlloVir Board of Directors AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company’s Chief Executive O...
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021 at 4:20 p.m. ET. The presentation will be available on the Investors & Press section of th...
- Subgroup analysis of Phase 2 CHARMS study shows rapid resolution of macroscopic hematuria in patients with virus-associated hemorrhagic cystitis treated with Viralym-M - Real world claims data analyses demonstrate worse clinical outcomes, and significantly higher healthcare ...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...